Literature DB >> 9175616

Modulation of the discriminative stimulus properties of cocaine: comparison of the effects of fluoxetine with 5-HT1A and 5-HT1B receptor agonists.

P M Callahan1, K A Cunningham.   

Abstract

The present investigation examined the ability of serotonin (5-HT) agonists to substitute for, or alter (i.e. enhance or antagonize), the discriminative stimulus properties of a moderately low dose of cocaine (5 mg/kg) utilizing a two-lever, water-reinforced FR 20 drug discrimination procedure in rats. In substitution tests, the 5-HT1A receptor partial agonists buspirone and gepirone, the 5-HT1A/B receptor agonist RU 24969 and the 5-HT1B/2C receptor agonist m-trifluoromethyl-phenylpiperazine (TFMPP) failed to substitute for the cocaine stimulus, although RU 24969 did engender a maximum of 72% cocaine-lever responding. Fluoxetine (4 mg/kg) engendered primarily saline-appropriate responding. In combination tests, a fixed dose of either fluoxetine (4 mg/kg), RU 24969 (0.5 mg/kg) or TFMPP (0.5 mg/kg) produced a leftward shift in the cocaine dose-response curve (0.313-5 mg/kg). In contrast, buspirone (2.5-20 mg/kg) resulted in a dose-dependent attenuation (approximately 60% reduction) of the cocaine stimulus. Moreover, a dose of 10 mg/kg of buspirone co-administered with various doses of cocaine (1.25-10 mg/kg) engendered a rightward shift in the cocaine dose-response curve. Gepirone in combination with cocaine neither enhanced nor antagonized the cocaine discriminative stimulus. Whereas 5-HT agonists do not fully substitute for cocaine, the present results demonstrate that 5-HT1B, but not 5-HT1A, receptor agonists can modulate the discriminative stimulus properties of cocaine in a manner similar to that observed following administration of the 5-HT reuptake inhibitor fluoxetine. The ability of buspirone, but not gepirone, to attenuate the cocaine stimulus probably reflects its dopamine (DA) D2 receptor antagonist properties and not its efficacy at 5-HT1A receptors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9175616     DOI: 10.1016/s0028-3908(97)00010-5

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  18 in total

1.  Differential modulation of cocaine's discriminative cue by repeated and variable stress exposure: relation to monoamine transporter levels.

Authors:  Stephen J Kohut; Kathleen L Decicco-Skinner; Shirin Johari; Zachary E Hurwitz; Michael H Baumann; Anthony L Riley
Journal:  Neuropharmacology       Date:  2012-03-23       Impact factor: 5.250

Review 2.  Kappa opioids as potential treatments for stimulant dependence.

Authors:  Thomas E Prisinzano; Kevin Tidgewell; Wayne W Harding
Journal:  AAPS J       Date:  2005-10-19       Impact factor: 4.009

3.  Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT2C Receptor.

Authors:  Christopher T Wild; Joanna M Miszkiel; Eric A Wold; Claudia A Soto; Chunyong Ding; Rachel M Hartley; Mark A White; Noelle C Anastasio; Kathryn A Cunningham; Jia Zhou
Journal:  J Med Chem       Date:  2018-04-13       Impact factor: 7.446

4.  Serotonin1B receptor stimulation enhances cocaine reinforcement.

Authors:  L H Parsons; F Weiss; G F Koob
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

5.  Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.

Authors:  Jack Bergman; Rebecca A Roof; Cheryse A Furman; Jennie L Conroy; Nancy K Mello; David R Sibley; Phil Skolnick
Journal:  Int J Neuropsychopharmacol       Date:  2012-07-25       Impact factor: 5.176

Review 6.  Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.

Authors:  K D Alex; E A Pehek
Journal:  Pharmacol Ther       Date:  2006-10-17       Impact factor: 12.310

7.  The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.

Authors:  Melanie A Paquette; Katherine Foley; Elizabeth G Brudney; Charles K Meshul; Steven W Johnson; S Paul Berger
Journal:  Psychopharmacology (Berl)       Date:  2009-03-13       Impact factor: 4.530

8.  Effects of chronic buspirone treatment on cocaine self-administration.

Authors:  Nancy K Mello; Peter A Fivel; Stephen J Kohut; Jack Bergman
Journal:  Neuropsychopharmacology       Date:  2012-10-17       Impact factor: 7.853

9.  Effects of chronic buspirone treatment on nicotine and concurrent nicotine+cocaine self-administration.

Authors:  Nancy K Mello; Peter A Fivel; Stephen J Kohut
Journal:  Neuropsychopharmacology       Date:  2013-01-21       Impact factor: 7.853

10.  Efficacy of buspirone for attenuating cocaine and methamphetamine reinstatement in rats.

Authors:  Keith L Shelton; Elizabeth S Hendrick; Patrick M Beardsley
Journal:  Drug Alcohol Depend       Date:  2013-01-29       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.